

# Piero Ruggenti

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6412221/piero-ruggenti-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58  
papers

5,206  
citations

29  
h-index

61  
g-index

61  
ext. papers

6,130  
ext. citations

11.4  
avg, IF

4.89  
L-index

#	Paper	IF	Citations
58	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.. <i>EClinicalMedicine</i> , <b>2022</b> , 43, 101240	11.3	1
57	Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 842473	5.6	0
56	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 827146	8.4	7
55	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial).. <i>Diabetes Research and Clinical Practice</i> , <b>2022</b> , 185, 109804	7.4	0
54	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <i>Acta Diabetologica</i> , <b>2021</b> , 59, 309	3.9	0
53	Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 575-587	6.9	0
52	Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003668	11.6	4
51	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 711915	8.4	0
50	Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003691	11.6	2
49	Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study. <i>Nephron</i> , <b>2021</b> , 145, 137-149	3.3	1
48	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.. <i>PLoS ONE</i> , <b>2021</b> , 16, e0261113	3.7	4
47	Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. <i>Nephron</i> , <b>2020</b> , 144, 195-203	3.3	2
46	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 74, 338-350	7.4	11
45	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 74, 224-238	7.4	22
44	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002777	11.6	21
43	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1177-1190	6.7	9
42	Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. <i>International Journal of Cardiology</i> , <b>2019</b> , 275, 145-151	3.2	10

41	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2018</b> , 6, 27-40	18.1	20
40	SaO006INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i317-i317	4.3	1
39	ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. <i>Current Opinion in Pharmacology</i> , <b>2017</b> , 33, 34-40	5.1	20
38	Dual renin-angiotensin system blockade for nephroprotection. <i>Nephrologie Et Therapeutique</i> , <b>2017</b> , 13 Suppl 1, S43-S45	0.6	6
37	Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1022-1030.e4	6.9	33
36	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2016</b> , 11, 785-94	6.9	26
35	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?. <i>CKJ: Clinical Kidney Journal</i> , <b>2016</b> , 9, 682-99	4.5	96
34	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. <i>CKJ: Clinical Kidney Journal</i> , <b>2016</b> , 9, 700-4	4.5	71
33	Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2015</b> , 3, 382-91	18.1	120
32	Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 2545-58	12.7	189
31	Paricalcitol for secondary hyperparathyroidism in renal transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 1205-14	12.7	44
30	Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study. <i>American Journal of Nephrology</i> , <b>2015</b> , 41, 16-27	4.6	4
29	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29, 1563-70	4.3	94
28	Dreaming of normoglycaemia with fewer diet restrictions. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2014</b> , 2, 350-1	18.1	1
27	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. <i>Blood</i> , <b>2014</b> , 124, 1715-26	2.2	220
26	Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2014</b> , 2, 417-26	18.1	221
25	Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab. <i>BMJ Case Reports</i> , <b>2014</b> , 2014,	0.9	5
24	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. <i>Lancet, The</i> , <b>2013</b> , 382, 1485-95	40	180

23	Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2013</b> , 1, 19-27	18.1	32
22	In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. <i>Journal of Immunology</i> , <b>2013</b> , 191, 2818-28	5.3	56
21	Mechanisms and treatment of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 1917-28.7	28.7	176
20	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. <i>Journal of Transplantation</i> , <b>2012</b> , 2012, 426042	2.3	8
19	Glomerular hyperfiltration and renal disease progression in type 2 diabetes. <i>Diabetes Care</i> , <b>2012</b> , 35, 2061-8	14.6	212
18	Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. <i>Hypertension</i> , <b>2011</b> , 58, 776-83	8.5	75
17	Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 783-9	6.9	104
16	Sirolimus therapy to halt the progression of ADPKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2010</b> , 21, 1031-40	12.7	127
15	Rituximab for membranous nephropathy and immune disease: less might be enough. <i>Nature Clinical Practice Nephrology</i> , <b>2009</b> , 5, 76-7		15
14	Developing regulatory-compliant electronic case report forms for clinical trials: experience with the demand trial. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2009</b> , 16, 404-8	8.6	31
13	Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 1973-85	12.7	85
12	Latest treatment strategies for membranous nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 3159-71	4	13
11	Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2006</b> , 1, 546-54	6.9	34
10	What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?. <i>Nature Clinical Practice Nephrology</i> , <b>2006</b> , 2, 250-1		2
9	Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. <i>Kidney International</i> , <b>2005</b> , 68, 206-16	9.9	189
8	Preventing microalbuminuria in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 1941-51	59.2	790
7	Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. <i>Lancet, The</i> , <b>2004</b> , 364, 503-12	40	136
6	Clinical practice. Nephropathy in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1145-51	59.2	455

5	Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. <i>Kidney International</i> , <b>2001</b> , 60, 1131-40	9.9	267
4	ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2001</b> , 12, 2832-2837	12.7	150
3	The role of protein traffic in the progression of renal diseases. <i>Annual Review of Medicine</i> , <b>2000</b> , 51, 315-27.4	27.4	53
2	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. <i>Lancet, The</i> , <b>1999</b> , 354, 359-64	40	657
1	The pathophysiology and management of thrombotic thrombocytopenic purpura. <i>European Journal of Haematology</i> , <b>1996</b> , 56, 191-207	3.8	78